Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

US7354933B2 · kind B2 · utility

Assignee

• AVENTIS PHARMA S.A. · FR

Inventors

• Marcel Patek · Tucson, US
• Anil Nair · Tucson, US
• Augustin Hittinger · Igny, FR
• Conception Nemecek · Thiais, FR
• Daniel Bond · Tucson, US
• Greg Harlow · Boulder, US
• Herve Bouchard · Thiais, FR
• Jacques Mauger · Tucson, US
• Jean-Luc Malleron · Marcoussis, FR
• Mark G. Palermo · Rindge, US
• Fahad Al-Obeidi · Tucson, US
• Thomas H. Faitg · Collegeville, US
• Hartmut Strobel · Liederbach, DE
• Sven Ruf · Mainz, DE
• Kurt Ritter · Heidelberg, DE
• Youssef El-Ahmad · Créteil, FR
• Dominique Lesuisse · Montreuil, FR
• Didier Benard · Villiers-le-Bel, FR

Key dates

• Filing date: Feb 2, 2004
• Grant date: Apr 8, 2008
• Expiry date: Nov 22, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a cyclic urea compound of formula I:as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.